Physician profile
Tisha S Wang
NPI 1164607461
$42,802.93
in general payments reported to CMS, 2019-2025
9 companies · $89.92 in 2025
The $89.92 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $1,138 · 2021: $21K · 2022: $12K · 2023: $6,009 · 2024: $715 · 2025: $89.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500 · Food and Beverage: $305 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
| Food and Beverage | $304.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Partner Therapeutics, INC. | $26,640.41 | 2021-2024 | Leukine |
| Glaxosmithkline, LLC. | $15,600.00 | 2019-2022 | |
| Grifols USA, LLC | $125.00 | 2019 | |
| Boston Scientific Corporation | $123.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $89.92 | 2025 | Dupixent |
| Alk-Abello, INC | $67.73 | 2022 | |
| Shionogi INC | $34.57 | 2023 | Fetroja |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tisha Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.